MEET THE TEAM
Sathyanarayana Reddy Perumalla, Ph.D.​
Founder and Director, Solid Form Screening and Analytical Services
Sathyanarayana Reddy Perumalla (Reddy) is an experienced solid state chemist and crystallographer. He has more than 15 years of experience in solid form screening, crystallization development, amorphization and through characterization of solid forms using variety of analytical tools including X-ray diffraction methods (both powder and single crystal), thermal, spectroscopic, and wet chemistry analytical techniques. Before starting the team at Seven Star, he worked at Teva pharmaceuticals as a lead solid form expert for about 3 years and supported many pre-formulation and formulation development programs. Throughout his career he has published 21 research articles in peer-reviewed international journals, out of which most of them are well received in the field and recognized as hot articles/front page cover articles/most original and most significant scientific findings articles by the publishers. In one of these articles, he proposed a new method of discovering new solid forms even for old molecules and termed as “CAB co-crystals” for the first time. Currently, he is also a scientific advisor to the editors of Journal of Pharmaceutical Sciences.
​
Larry Rosen, Ph.D
Principal Consultant
Larry Rosen has over 30 years of experience in the development and commercialization of small molecule drug products. From 1993 to 2015, he held various individual contributor and management roles in R&D and manufacturing at Merck, playing a key role in the development and global approval of seven medicines. Between 2005 and 2010, he contributed to the implementation of Quality by Design practices in Merck’s early- and late-stage development functions. From 2015 to 2023, Larry served as Vice President of Pharmaceutical Product Development at Venatorx Pharmaceuticals, leading drug product development for two novel antibacterial drug candidates. His expertise spans pharmaceutical materials science, formulation design, process development, scale-up, and technology transfer of solid oral dosage forms. He has extensive experience in developing both conventional and enabled solid oral dosage forms from early-phase development through commercialization.
Doug Claney, Ph.D
CMC Pharmaceutical consultant,
Quality Assurance and Drug Product Development
Doug Claney has worked for over 30 years in pharmaceutical manufacturing in leadership roles in Quality and drug development; and also has experience with small molecule and large molecule drug products. In the area of Quality, Doug has “hands-on” experience in GMP facility auditing, PAI readiness, document systems, SOP and MBR writing, CAPA and Quality investigations, batch record review and Quality Release, and all other Quality systems. In the area of Drug product Development, Doug has experience with drug process development form stage-1 through commercial scale-up, selecting and working with CMOs, product/process monitoring, project management, process validation, failure investigations, risk assessments, and project management leadership.
